Work

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.9057

Authors: Alexander I. Spira, Frederick Hugh Wilson, Geoffrey Shapiro, Christophe Dooms, Alessandra Curioni-Fontecedro, Taito Esaki, Fabrice Barlesi, Kim Cocks, Andrew Trigg, Kendall Stevinson, Tara Matsuda, Qui Tran, Jhanelle Elaine Gray

Institutions: Virginia Cancer Specialists, Dana-Farber Cancer Institute, Universitair Ziekenhuis Leuven, KU Leuven, University Hospital Zurich, National Hospital Organization Kyushu Cancer Center, Institut Gustave Roussy, Adelphi Group (United Kingdom), Amgen (United States), Moffitt Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3166520558

Cites:

Cited by: 13

Related to: 10